Scancell and PharmaJet to use Stratis® IM Needle-free delivery System for SCIB1/iSCIB1+ vaccine for Advanced Melanoma
Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: “Securing long term supply for the PharmaJet Stratis® Intramuscular Needle-free Injection System is an important step in allowing the clinical and commercial development of SCIB1/iSCIB1+. We are pleased that PharmaJet’s delivery system works effectively with our SCIB1/iSCIB1+ therapeutic cancer vaccines and offers a well-received immunisation for patients. Our ultimate goal for Scancell is to deliver an off the shelf, safe, tolerable, effective therapy that can provide potent and durable anti-tumour responses for unresectable stage IV melanoma which currently has a 5-year survival of 35%, according to the SEER database, and we believe this agreement will bring us another step closer to achieving this goal.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000